Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $5,646.0K | $124.4M | ($107.7M) | ($114.5M) | ($89.8M) | ($74.1M) | ($97.5M) | ($205.2M) | $457.7M | $760.0M | $838.4M | $1,251.9M | $1,330.7M | $2,079.6M | $2,534.4M | $2,209.8M | $3,576.6M | $8,946.8M | $4,738.9M | $4,047.1M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Regeneron Pharmaceuticals, Inc.'s last 12-month Operating Income is $4,004.4M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Regeneron Pharmaceuticals, Inc.'s Operating Income growth was (5.1%). The average annual Operating Income growth rates for Regeneron Pharmaceuticals, Inc. have been 0.1% over the past three years, 12.2% over the past five years.
Over the last year, Regeneron Pharmaceuticals, Inc.'s Operating Income growth was (5.1%), which is lower than industry growth of (0.1%). It indicates that Regeneron Pharmaceuticals, Inc.'s Operating Income growth is Bad.